Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease

NCT ID: NCT00316121

Last Updated: 2011-03-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety and effectiveness of HEALOS compared with autograft using the transforaminal lumbar interbody fusion (TLIF) method.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

HEALOS and Leopard Cage

Intervention Type DEVICE

Placement in interbody space

2

Group Type ACTIVE_COMPARATOR

Leopard Cage and Autograft

Intervention Type DEVICE

Placement in the interbody space

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HEALOS and Leopard Cage

Placement in interbody space

Intervention Type DEVICE

Leopard Cage and Autograft

Placement in the interbody space

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persistent back and/or leg pain refractory to 6 months of non-surgical therapy
* Male or female 18 to 70 years of age (inclusive)
* Objective evidence of significant disc degeneration at one or two adjacent lumbar level(s) from L2/L3 to L5/S1

Exclusion Criteria

* Significant disc degeneration at more than two adjacent levels
* Greater than Grade II spondylolisthesis
* Prior fusion surgery of the lumbar spine (prior discectomies and intradiscal electrothermal therapy \[IDET\] are allowed)
* Insulin-dependent diabetes mellitus
* Pregnant or lactating, or wishes to become pregnant within the 24 month duration of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DePuy Spine

INDUSTRY

Sponsor Role collaborator

Advanced Technologies and Regenerative Medicine, LLC (ATRM)

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Advanced Technologies and Regenerative Medicine, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Little Rock, Arkansas, United States

Site Status

Beverly Hills, California, United States

Site Status

Brandon, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Savannah, Georgia, United States

Site Status

Chicago, Illinois, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Annapolis, Maryland, United States

Site Status

Billings, Montana, United States

Site Status

Williamsville, New York, United States

Site Status

Norwood, Ohio, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Eugene, Oregon, United States

Site Status

Temple, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Spokane, Washington, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

05-HEALOS-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Transforaminal Lumbar Interbody Fusion (TLIF)
NCT04073563 ACTIVE_NOT_RECRUITING NA